'hirsutism'. True hirsutism is hair growth restricted to part or all of the male sexual pattern, and implies androgen excess. In our patient and in others receiving CyA, excessive hair growth has not been restricted to the male distribution, and a r-ecent report confirms that androgen levels are not raised (Margreiter et al. 1983 ). The term which should properly be used for the hair growth induced by CyA is 'hypertrichosis', meaning growth of hair excessive for the site on the body and for the age of the patient. The phenomenon has also been observed in nude mice treated with CyA (Pendry & Alexander 1982). As with other drugs such as phenytoin and minoxidil which cause hypertrichosis, the mechanism by which CyA stimulates hair growth is unclear.
The development of skin tumours in a patient receiving CyA has not previously been reported. Several forms of malignancy, including skin tumours, occur more frequently as a result of conventional immunosuppressive therapy (Penn 1981), but although an increased incidence of. lymphomas has been recorded with CyA treatment (Morris 1983) , no significant increase in the incidence of other neoplasms has been observed to date in patients receiving this drug. Our patient developed multiple synchronous squamous cell carcinomas and premalignant keratoses on light-exposed skin 8 months after conversion to CyA. It seems very likely that their development was related to administration of the drug, although the effects of 6 years of conventional immunosuppression and 55 years of ultraviolet light exposure presumably predisposed the patient to the development of skin malignancy (Sheil et al. 1979) .
There is no known relationship between hypertrichosis and the development of cutaneous squamous cell carcinoma, but it would appear that in this patient CyA stimulated a proliferative response in both the skin and its appendages. The previously unreported association of dermatomyositis and a salivary pleomorphic adenoma is described. Although considered overall to be benign, the parotid tumour showed some histological features typically associated with malignant mixed salivary gland tumour. Furthermore, the rapid response of the dermatomyositis to treatment following removal of the neoplasm may suggest a causative relationship.
Case report
A 71-year-old Caucasian woman was admitted with a three-week history of a florid red rash, typical of dermatomyositis, muscle weakness and general malaise. In addition, the patient had noticed swelling of the left-hand side of the face. Previously the patient had been well and had no other symptoms but was receiving thyroid extract for hypothyroidism, diagnosed in childhood. On examination, the patient had myxoedematous facies, a rash characteristic of dermatomyositis and extreme weakness of the proximal and truncal muscle groups. There was a mobile non-tender mass in the left parotid region measuring 3 x 2 in (7.6 x 5.1 em). There was no associated facial weakness. General examination, including rectal and gynaecological examination, was otherwise normal.
A raised creatinine phosphokinase of 292 V /1 (normal <60), lactate dehydrogenase of 884 V/I (normal <45) and an electromyogram typical of myositis in the presence of characteristic cutaneous histopathology, confirmed the diagnosis of dermatomyositis. The antinuclear factor was weakly positive at I : 10; the full blood picture, erythrocyte sedimentation rate, thyroid function tests and blood sugar level were normal.
Investigations for occult malignancy including barium studies, chest X-ray, intravenous pyelogram, mammogram, abdominal and pelvic ultrasound and serum protein levels were negative. Histopathological examination' of the parotid neoplasm revealed an encapsulated pleomorphic adenoma ( Figure I ). However, foci of necrosis were seen in several sections and adjacent areas showed many cells with atypical nuclei (Figure 2 ). In spite of these unusual changes the tumour was considered benign. Complete excision of the mass was undertaken.
The patient's dermatomyositis was initially controlled by prednisolone 60 rug/day, but following removal of the adenoma a reduction of the dosage to 15 mg daily was possible without any clinical or biochemical relapse of the dermatomyositis.
Discussion
Pleomorphic adenoma is a benign tumour which, because of finger-like extensions through the capsule, has a propensity for local recurrence after excision. Some authors note that malignant mixed parotid tumour may arise in a benign pleomorphic adenoma (Foote & Frazell 1953 , Saksala et al. 1970 ) and, indeed, Livolsi & Perzin (1977 consider that tumours with the histology of pleomorphic adenoma containing areas of atypicality and necrosis may represent carcinoma-in-situ. However, Gerughty et al. (1969) consider that mixed malignant lesions arise de novo and are not transformed from benign lesions. Rarely benign tumours may show typical benign histology but be capable of metastasis. Three tumours with typical benign histology which metastasized to the lung and bone have been described (Gerughty et al. 1969) , the metastases showing the same benign histology as the primary tumour.
The association of salivary pleomorphic adenoma and dermatomyositis has never previously been recorded in the English literature (Callen 1982 , Barnes 1976 . The patient's rapid clinical and biochemical response to treatment following removal of the tumour suggests a relationship between the tumour and dermatomyositis, and may imply that the unusual histological features found in this case represented carcinomatous change.
